Andere Sprachen Isofol Medical AB

Aktien

A2DPV6

SE0009581051

ISOFOL

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:24:20 29.04.2024			% 5 Tage	% 1. Jan.
0,738 ^SEK	+6,34 %		+2,64 %	+1,10 %

20.02.	Isofol Medical AB (publ) meldet Ergebniszahlen für das vierte Quartal zum 31. Dezember 2023	CI
20.02.	Isofol Medical AB (publ) berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023	16.04.
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)	05.04.
Isofol Medical : Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19.03.
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19.03.
Isofol presents a clinical development plan for arfolitixorin	19.03.
Isofol Medical : invites to investor meeting on March 19	01.03.
Isofol Medical AB (publ) publishes year-end report, January - December 2023	20.02.
Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20.02.
Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023	20.02.
Isofol's Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19	14.02.
Isofol Medical Hires New CFO	11.01.
Isofol appoints Magnus Hurst as new Chief Financial Officer	10.01.
Isofol Medical AB Announces Chief Financial Officer Changes	10.01.
Isofol Medical Names New CEO	09.01.
Isofol appoints Petter Segelman Lindqvist as new CEO	09.01.
Isofol Medical AB Announces CEO Changes	09.01.
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024	04.01.
Isofol Medical AB Announces Board Elections	04.01.
Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects	28.12.
Isofol Medical AB Presents Additional Results from Laboratory Tests with Arfolitixorin Showing Supplementary Effects	28.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Isofol Medical AB

Aktien

A2DPV6

SE0009581051

ISOFOL

Andere Sprachen

Filter